Share

    


Home / Search Results

Search Results

You searched for:

ACCCBuzz spoke with Dr. Gabriela Hobbs, MD, at Massachusetts General Hospital Cancer Center to learn how to best manage patients' care for those with myelofibrosis.
ACCCBuzz spoke with Dr. Jessica Unzaga at Baptist Health’s Miami Cancer Institute, to help consider the use of triplet vs. quadruplet regimens in the treatment of multiple myeloma.
With the treatment of chronic lymphocytic leukemia (CLL) shifting substantially in the last five years, learn how ACCC is supporting oncology professionals in integrating oral oncolytics in CLL practice.
Measurable residual disease (MRD) has gained traction as a compelling marker for disease status across various hematologic malignancies, including multiple myeloma. Learn how MRD is uniquely suited to help evaluate the depth of treatment response.
With data already demonstrating the role of MRD for CLL response assessment and prognosis, cancer programs should prepare themselves for implementation of MRD testing for appropriate patients.
The purpose of this study was to assess patient, disease, and medication-related factors that affect the rate of unplanned readmissions before next chemotherapy cycle or within 30 days since last chemotherapy admission in patients with hematologic malignancies.